1 completed, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Bilix Co.,Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE) BX-001N Experimental group 1, BX-001N Experimental group 2, Placebo group 1 - Ischemia Reperfusion Injury, Cardiac Surgery Associated - Acute Kidney Injury | Phase 2 | Recruiting | Bilix Co.,Ltd. | 50 | 2025-08-26 | 2026-07-01 |
| A Study to Evaluate the Safety and Pharmacokinetics of BX-001N in Healthy Participants BX-001N Part 1, BX-001N Part 2, Placebo - Ischemia-reperfusion Injury | Phase 1 | Completed | Bilix Co.,Ltd. | 51 | 2023-11-17 | 2025-04-17 |
Australia (1) · South Korea (1)
Angela C Rowland, Dr (1) · Myung Lip Kim, Chief Executive Officer (1)